Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
166.245 USD
0.96%
Updated:
Apr 19, 2024
Abbvie Inc
Total Receivables
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Total Receivables Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$7.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
31%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Total Receivables
$631.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
33%
|
CAGR 10-Years
36%
|
See Also
What is Abbvie Inc's Total Receivables?
Total Receivables
11.2B
USD
11.2B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Total Receivables amounts to 11.2B USD.
What is Abbvie Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
9%
9%
Over the last year, the Total Receivables growth was -1%. The average annual Total Receivables growth rates for Abbvie Inc have been 8% over the past three years , 16% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
